Obesity drug approved as problem grows across the worldBMJ 2001; 323 doi: https://doi.org/10.1136/bmj.323.7319.955/a (Published 27 October 2001) Cite this as: BMJ 2001;323:955
- Roger Dobson
The National Institute for Clinical Excellence, the government's medicines watchdog, has advised the NHS in England and Wales that the anti-obesity drug, sibutramine (Reductil), should be available on prescription.
It has recommended that sibutramine be part of an overall treatment plan for obese patients. It should be available for people aged 18-65 years who have made serious attempts to lose weight through dieting, exercise, or other behaviour changes, who have a body mass index (kg/m2) of 27.0 or more and who have other significant diseases, such as type 2 diabetes. It should also be made available for anyone with a body mass index of more than 30.0, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial